This review highlights progress and ongoing pharmacokinetic challenges in developing IRAP inhibitors as cognitive enhancers within the renin-angiotensin system.
No takes yet. Share an insight, caveat, or question.
Pharmacokinetic barriers preclude clinical use of IRAP inhibitors; leaves open their viability as cognitive enhancers.
Andersson et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: